Health Care [ 5/12 ] | Biotechnology [ 29/74 ]
NASDAQ | Common Stock
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia.
It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders.
In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease.
Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3.
It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; SanofiS. A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 13, 25 | 0.06 Increased by +105.45% | -0.14 Increased by +142.52% |
| Oct 31, 24 | -0.87 Decreased by -175.65% | -0.93 Increased by +6.45% |
| Aug 1, 24 | -0.13 Increased by +94.12% | -1.08 Increased by +87.96% |
| May 2, 24 | -0.52 Increased by +62.86% | -1.18 Increased by +55.93% |
| Feb 15, 24 | -1.10 Increased by +34.52% | -1.32 Increased by +16.67% |
| Nov 2, 23 | 1.15 Increased by +142.75% | -1.34 Increased by +185.82% |
| Aug 3, 23 | -2.21 Increased by +3.49% | -1.37 Decreased by -61.31% |
| May 4, 23 | -1.40 Increased by +30.00% | -1.77 Increased by +20.90% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 500.92 M Decreased by -33.26% | -111.57 M Decreased by -175.51% | Decreased by -22.27% Decreased by -213.14% |
| Jun 30, 24 | 659.83 M Increased by +107.00% | -16.89 M Increased by +93.88% | Decreased by -2.56% Increased by +97.04% |
| Mar 31, 24 | 494.33 M Increased by +54.82% | -65.94 M Increased by +62.13% | Decreased by -13.34% Increased by +75.54% |
| Dec 31, 23 | 439.72 M Increased by +31.25% | -137.87 M Increased by +33.55% | Decreased by -31.35% Increased by +49.37% |
| Sep 30, 23 | 750.53 M Increased by +183.96% | 147.75 M Increased by +136.40% | Increased by +19.69% Increased by +112.82% |
| Jun 30, 23 | 318.75 M Increased by +41.78% | -276.02 M Increased by +0.50% | Decreased by -86.59% Increased by +29.82% |
| Mar 31, 23 | 319.29 M Increased by +49.72% | -174.10 M Increased by +27.56% | Decreased by -54.53% Increased by +51.62% |
| Dec 31, 22 | 335.04 M Increased by +29.59% | -207.49 M Increased by +19.72% | Decreased by -61.93% Increased by +38.05% |